Clinical Trial Update: Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B [Phase 1]

View source ↗

Summary

Phase 1 ascending-dose study of SB-FIX, a zinc finger nuclease–based genome editing therapy for Hemophilia B, was terminated with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• SB-FIX

Snippet

Sponsor: Sangamo Therapeutics | Conditions: Hemophilia B | Phase 1 | Status: TERMINATED | Results posted: 2024-07-19